New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
PK modeling data provide insights into potential dosing conversions and strategies for switching to UZEDY from a long-acting injectable (LAI) formulation of risperidone... Read more.
Wipro Appoints Srini Pallia as CEO & Managing Director
EAST BRUNSWICK, N.J. & BENGALURU, India–(BUSINESS WIRE)–$WIPRO #CEO–Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology... Read more.
The United States Army and United Football League Announce Exclusive Partnership; U.S. Army Becomes the Presenting Partner of the UFL
WASHINGTON & ARLINGTON, Texas–(BUSINESS WIRE)–The United Football League (“UFL”) today announced an exclusive partnership with The United States... Read more.
Tempus Introduces Workspaces into its Lens Data Analytics Platform
Lens is trusted by nearly 100 institutions to uncover novel insights CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision... Read more.
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse SOMERSET, N.J.–(BUSINESS WIRE)–Legend... Read more.
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s ENHERTU that showed clinically meaningful responses across a broad range of tumors ENHERTU now... Read more.
Avangrid Statement on Gas Subsidiaries’ Response to 4.8 Magnitude Earthquake
New York State Electric & Gas (NYSEG), Southern Connecticut Gas (SCG), Connecticut Natural Gas (CNG), and Berkshire Gas Company (BGC) assessing for damage to... Read more.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
Based on three Phase II trials of AstraZeneca and Daiichi Sankyo’s ENHERTU which showed clinically meaningful responses across a broad range of tumors ENHERTU... Read more.
AMYLYX PHARMACEUTICALS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. – AMLX
NEW ORLEANS–(BUSINESS WIRE)–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti,... Read more.
INOTIV INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inotiv, Inc. – NOTV
NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC... Read more.